DERIVATIVES OF 6-SUBSTITUTED TRIAZOLOPYRIDAZINES AS REV-ERB AGONISTS
申请人:GENFIT
公开号:US20150038503A1
公开(公告)日:2015-02-05
The present invention provides novel 6-substituted [1,2,4]triazolo[4,3-b]pyridazines that are agonists of Rev-Erb. These compounds, and pharmaceutical compositions comprising the same, are suitable means for treating any disease wherein the activation of Rev-Erb has therapeutic effects, for instance in inflammatory and circadian rhythm-related disorders or cardiometabolic diseases.
Derivatives of 6-substituted triazolopyridazines as Rev-Erb agonists
申请人:GENFIT
公开号:US10799510B2
公开(公告)日:2020-10-13
The present invention provides novel 6-substituted [1,2,4]triazolo[4,3-b]pyridazines that are agonists of Rev-Erb. These compounds, and pharmaceutical compositions comprising the same, are suitable means for treating any disease wherein the activation of Rev-Erb has therapeutic effects, for instance in inflammatory and circadian rhythm-related disorders or cardiometabolic diseases.
Radical Truce-Smiles reactions on an isoxazole template: Scope and limitations
作者:Srood O. Rashid、Sultan S. Almadhhi、David J. Berrisford、James Raftery、Inigo Vitorica-Yrezabal、George Whitehead、Peter Quayle
DOI:10.1016/j.tet.2019.03.015
日期:2019.4
promotor in the radical Truce-Smiles reactions of 2-(((3,5-dimethylisoxazol-4-yl)sulfonyl)oxy)benzenediazonium salts has been investigated in detail. During these reactions the desired Truce-Smiles rearrangement (via an ipso-substitution reaction) is accompanied by the formation of a number of by-products including dihydrobenzo[5,6][1,2]oxathiino[3,4-d]isoxazole 4,4-dioxides, dioxidobenzo[e][1,2]ox